Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06706817 · ClinicalTrials.gov registry record · Phase 3

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

A Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
180
Enrollment target
20
Study locations

NCT06706817 is a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 180 participants, above the 126-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06706817, a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma. Study details include: 1. The study duration will be up to 40 weeks. 2. The treatment duration will be up to 24 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).

Conditions Studied

Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • COMBINATION_PRODUCT Tezepelumab

Study Locations (20)

Other

  • Research Site - Plovdiv
  • Research Site - Sofia
  • Research Site - Sofia
  • Research Site - Le Kremlin-Bicêtre
  • Research Site - Lille
  • Research Site - Marseille
  • Research Site - Nantes
  • Research Site - Pierre-Bénite
  • Research Site - Poitiers
  • Research Site - Toulouse
  • Research Site - Düsseldorf
  • Research Site - Marburg
  • Research Site - Tübingen

Quebec

  • Research Site - Québec
  • Research Site - Québec

California

  • Research Site - Newport Beach

Illinois

  • Research Site - Chicago

Massachusetts

  • Research Site - Chestnut Hill

Missouri

  • Research Site - Columbia

Ontario

  • Research Site - Hamilton

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2024-12-03
Est. Completion 2027-01-13
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06706817

The ClinicalTrials.gov registry entry for NCT06706817 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 126-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (43% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps appearing as the primary indexed condition, and to 1 intervention - of which Tezepelumab is the first listed.

NCT06706817 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Quebec, California.

Frequently Asked Questions

What is clinical trial NCT06706817 about?

NCT06706817 is a clinical study titled "A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab". The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma. Study details include: 1. The study duration will be up to 40 weeks. 2. The treatment duration will be up to 24 weeks. 3. ...

What is the current status of trial NCT06706817?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2024-12-03. Estimated completion is 2027-01-13.

What conditions does trial NCT06706817 study?

This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps.

What interventions are being tested in trial NCT06706817?

The interventions under investigation include: Tezepelumab (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06706817?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06706817 being conducted?

This trial has 20 study locations across California, Illinois, Massachusetts, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Rhinosinusitis With Nasal Polyps

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Rhinosinusitis With Nasal Polyps

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.